Efficacy, Safety and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Phase 3
942
about 4.4 years
40–80
48 sites in AZ, CA, FL +14
About this study
This trial is testing a treatment called lunsekimig compared to a placebo in adults with COPD that can't be controlled. The goal is to see if lunsekimig helps improve symptoms and is safe for people with COPD.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Lunsekimig
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Secondary: Change from baseline in post-Bronchodilator Forced Expiratory Volume in 1 second (post-BD FEV1), Change from baseline in pre-Bronchodilator Forced Expiratory Volume in 1 second (pre-BD FEV1), Change from baseline in the Chronic airways assessment Test (CAAT) score, Change from baseline in the E-RS:COPD total score, Change from baseline in the SGRQ-C total score, Incidence of participants with TEAEs, including AESIs, and SAEs
Respiratory